Glycopyrrolate/formoterol fumarate vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere
Marketed by AstraZeneca
NCT03324607 · Phase 2/3 · completed
The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.
Reported efficacy
Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)
Result source: NCT03324607
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrrolate/formoterol fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Trial running · NCT06474039 |
| Trough FEV1, change | —Not reported | 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | —Not reported | —Trial running · NCT06474039 |
| TDI focal score | —Not reported | —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- Glycopyrrolate/formoterol fumarate
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Glycopyrrolate/formoterol fumarate: 2 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrrolate/formoterol fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Dropout rate | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | 11.7%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result— NCT03081156 · Phase 4 · registry result, not featured evidence | 4%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%a NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 show 1 more result12.5% NCT03081156 · Phase 4 · registry result, not featured evidence | 3.5%62.5/25 µgb NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — | 62.5/25 µgb headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrrolate/formoterol fumarate
Umeclidinium/Vilanterol
show 3 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Umeclidinium/Vilanterol's landscape